Status:
COMPLETED
Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI)
Lead Sponsor:
Santen Pharmaceutical Co., Ltd.
Conditions:
Macular Edema Following Branch Retinal Vein Occlusion
Eligibility:
All Genders
20+ years
Phase:
PHASE2
PHASE3
Brief Summary
This study will evaluate the efficacy and safety of Betamethasone Microsphere (DE-102) for macular edema following branch retinal vein occlusion
Eligibility Criteria
Inclusion
- 20 years of age or older
- Diagnosis of macular edema following branch retinal vein occlusion
Exclusion
- BCVA ETDRS letter score in non-study eye \< 35
- Known steroid-responder
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01512901
Last Update
July 21 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Santen study sites
Osaka, Japan
2
Santen study sites
Seoul, South Korea